Study of SCY-635, Pegasys and Copegus in Hepatitis C

Phase 2

Completed

• Conditions: Hepatitis C Infection
• Interventions: Drug: Placebo; Drug: SCY-635; Drug: Pegasys; Drug: Copegus

• Registration Number: NCT01265511
• Lead Sponsor: Scynexis, Inc.

Brief Summary

This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.

Detailed Description

Objectives:

The primary objective of this Phase 2a study was to assess the effect of treatment with SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.

The secondary objective of the study was to evaluate the safety and pharmacokinetics (PK) of SCY-635 when given in combination with PegIFN α-2a and RBV.

Primary Endpoints:

Proportion of subjects in each cohort with an undetectable serum HCV RNA level at Week 4 of treatment

Secondary Endpoints:

Adverse events and clinical laboratory assessments, including tests of liver function Proportion of subjects achieving complete early virologic response (cEVR, defined as an undetectable serum HCV RNA level at Week 12) Proportion of subjects achieving partial early virologic response (pEVR, defined as a detectable serum HCV RNA level with ≥ 2 log10 reduction in serum HCV RNA from Baseline to Week 12) Proportion of subjects achieving an undetectable serum HCV RNA level at Week 24 Pharmacokinetic assessments of SCY-635 when given in combination with PegIFN α-2a and RBV; trough concentrations of PegIFN α-2a and RB

Study Timeline

• Study Start: 2010-11
• Study First Submitted: 2010-11-23
• Study First Submitted QC: 2010-12-22
• Study First Posted: 2010-12-23
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Results First Submitted: 2014-10-22
• Status Verified: 2017-07
• Results First Submitted QC: 2017-07-18
• Last Update Submitted: 2017-07-18
• Results First Posted: 2017-08-18
• Last Update Posted: 2017-08-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

• Quantifiable serum levels of HCV-specific RNA in excess of 100,000 IU/mL

• Chronic HCV status

• HCV genotype 1 infection and IL28B genotype of C/T or T/T

• Liver biopsy results within 3 years prior to screening indicating the absence of cirrhosis

  *If no previous biopsy is available, a biopsy must be performed during the screening period to qualify for randomization

• Body mass index (BMI) between 18 and 38 kg/m2

• Laboratory variables within acceptable ranges:

  • ALT/AST < 3 × ULN;
  • HgB > 12g/dL for females, > 13 g/dL for males;
  • total WBC count > 3000/mm3 and ANC > 1500/mm3;
  • platelets > 100,000/mm3;
  • prothrombin time (or INR) ≤ 1.2 × ULN;
  • serum albumin ≥ 3.4 g/dL;
  • total bilirubin WNL;
  • serum creatinine WNL; if serum creatinine is > ULN, then calculated creatinine clearance must be > 100 mL/min (by Cockcroft-Gault formula) for subject to be eligible

• Subjects of childbearing potential (i.e., not surgically sterile or postmenopausal) must agree to use 2 forms of contraception from Screening until 24 weeks after completion of treatment with RBV

• Negative urine testing for amphetamines and cocaine at Screening.

• If female, the subject has a negative pregnancy test at Screening and on study Day 1

Read More

Exclusion Criteria

• History of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease

• Females who are pregnant or breastfeeding

• Males with partners who are pregnant or are planning to become pregnant

• HCV genotype other than genotype 1 and an IL28B genotype of C/C

• Seropositive for HIV-1 or HIV-2 or hepatitis B virus (HBV) surface antigen (HBsAg)

• Use of any investigational agent within 3 months prior to dosing

• Received any prior FDA-approved or investigational drug or drug regimen for the treatment of hepatitis C

• Evidence of cirrhosis on a previous liver biopsy

• Evidence of decompensated liver disease

• Recipient of an organ transplant

• Evidence of hepatocellular carcinoma

• Evidence of ongoing alcohol or substance abuse

• Poorly-controlled diabetes mellitus

• Congestive heart failure or unstable cardiopulmonary condition, renal disease, or hemoglobinopathy (sickle cell anemia or thalassemia

• History of seizure disorder

• History of severe psychiatric illness, including severe depression, history of suicidal ideation, suicidal attempts, related hospitalizations, bipolar disorder, or psychosis requiring medication

• Concurrent medical condition or laboratory abnormality that would constitute a contra-indication for interferon use

• History of unstable thyroid disease that would preclude administration of interferon-based therapy

• Medical condition that requires use of systemic corticosteroids

• Received warfarin or other anticoagulants during the 21 days immediately prior to Screening, or is expected to require warfarin or other anticoagulants during the study.

• One or more additional known primary or secondary causes of liver disease, other than hepatitis C

• Any other concurrent medical condition likely to preclude compliance with the schedule of evaluations, or likely to confound the efficacy or safety observations

• 12-lead ECG showing the following:

  • Corrected QTc interval ≥ 450 msec (Bazett's correction);
  • QRS > 120 msec;
  • Clinically significant abnormalities;

• Severe retinopathy or other significant ophthalmological disorder

• Use of any herbal supplements within 28 days prior to dosing.

• The use of CYP3A inducers or inhibitors for at least 2 weeks prior to initiation of treatment through Week 6

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Pegasys	Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635 600 mg	Copegus	SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo	Placebo	Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635 600 mg	Pegasys	SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
Placebo	Copegus	Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks
SCY-635 600 mg	SCY-635	SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks

Primary Outcome Measures

Name	Time	Method
Undetectable HCV RNA	Week 4

Secondary Outcome Measures

Name	Time	Method
Undetectable HCV RNA	Week 24
Partial Early Virologic Response	Week 12	Proportion of subjects with detectable HCV RNA that achieve a \> or = 2 log reduction in HCV RNA from baseline to Week 12

Trial Locations

Locations (4)

Alamo Medical Research; 🇺🇸 San Antonio, Texas, United States

Quest Clinical Research; 🇺🇸 San Francisco, California, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Fundacion de Investigation de Diego; 🇵🇷 San Juan, Puerto Rico